Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

NCT00938392 PHASE3 COMPLETED Results posted

The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	726
Start date	Thu Jul 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Oct 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza

Interventions

• GSK investigational FluNG vaccine GSK2186877A, aged lot
• GSK investigational FluNG vaccine GSK2186877A, fresh lot

Countries

Slovakia, Estonia